These data explain why we tracked the effect of KD on the key indicators of MS (fasting glycemia, triglycerides, HDL-C, AH), as well as other markers of impaired metabolic health—fasting insulin levels, IR indices (HOMA-IR, QUICKI), adiponectin, uric acid, NAFLD, etc. This evidence concerns the gene ADIPOQ and myeloid sarcoma.